UCSD John B. West Distinguished Lecture Series, Sponsored by MediPines | Featuring Nobel Laureate Dr. Gregg L Semenza

MediPines, the pioneering market leader in non-invasive pulmonary gas exchange technology, and maker of AGM100, will sponsor this year’s annual UCSD John B. West Distinguished Lecture event featuring Nobel Laureate Gregg L. Semenza, MD, PhD.

The lecture, titled “Hypoxia-Inducible Factors in Physiology and Medicine,” will take place on August 7, 2023 at noon pacific time via livestream from UCSD.

“We’re honored to be hosting the esteemed Dr. Semenza, a pioneer and expert on studying how cells adapt to changing oxygen levels and molecular mechanisms of oxygen homeostasis,” said Dr. Jason Yuan, Professor and Director, Section of Physiology of the Division of Pulmonary, Critical Care and Sleep Medicine at UCSD. Dr. Yuan is a co-author of Ganong’s Review of Medical Physiology.

“We’re delighted to have Dr. Gregg L Semenza speak on this very important topic in medicine. He is an outstanding example of a physician scientist whose work has set the bedrock for numerous clinical innovations,” said MediPines CEO, Steve Lee, who co-invented non-invasive pulmonary gas exchange monitoring technology, AGM100, with Dr. West.

Dr. Semenza, the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins University, was awarded the Nobel Prize in Physiology or Medicine, with William G. Kaelin, Jr. and Peter J. Ratcliffe in 2019 for his groundbreaking discovery of the hypoxia-inducible factor (HIF) protein. His research on molecular mechanisms of oxygen homeostasis and oxygen sensing has generated more than 500 research articles.

After introductory notes by Zea Borok, MD (Chair of Medicine, UCSD); Jess Mandel, MD, (Chief of Pulmonary, Critical Care and Sleep Medicine, UCSD); John B. West, MD, PhD, DSc (Emeritus Professor of Medicine and Physiology at UCSD); and Steve Lee (CEO of MediPines), Dr. Semenza will deliver his lecture. After the presentation and a brief Q&A session, Dr. West will present a plaque and honorarium to Dr. Semenza.

As part of the program, there will also be a clinical presentation from a UCSD physician-scientist after the lecture.

Registration for the event can be accessed here: https://medipines.com/jbwlecture2023

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.